U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H18N2O2
Molecular Weight 234.2942
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CP1-1189

SMILES

CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C

InChI

InChIKey=DJKNRCWSXSZACF-UHFFFAOYSA-N
InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)

HIDE SMILES / InChI

Molecular Formula C13H18N2O2
Molecular Weight 234.2942
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

CPI-1189 is a synthetic benzamide with antioxidant properties that blocks tumor necrosis factor-alpha (TNFalpha) effects in animal models. It has neuroprotective properties in model systems for HIV-associated neurotoxicity and thus is a candidate for neuroprotective therapy in humans with HIV-associated CNS disease. CPI-1189 was at the phase II stage of clinical development for the treatment of dementia associated with Parkinson's disease and AIDS Dementia Complex, however, development has been discontinued.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26 μg/mL
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP1-1189 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
413 μg × h/mL
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP1-1189 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.9 h
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP1-1189 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex.
2000 Dec
CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties?
2000 Mar 10
A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.
2002 Nov 26
Patents

Sample Use Guides

Sixty-four subjects with mild to moderate HIV-associated cognitive-motor impairment were randomized to receive either placebo or 50 or 100 mg daily of CPI-1189 in addition to optimal HIV therapy.
Route of Administration: Oral
CPI-1189 inhibits p38-MAPK phosphorylation at concentrations of 10 nM or less.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:42:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:42:47 GMT 2023
Record UNII
9JX1L8VH4Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CP1-1189
Common Name English
CPI-1189
Code English
BENZAMIDE, 4-(ACETYLAMINO)-N-(1,1-DIMETHYLETHYL)-
Systematic Name English
Code System Code Type Description
CAS
183619-38-7
Created by admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
PRIMARY
PUBCHEM
151118
Created by admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
PRIMARY
FDA UNII
9JX1L8VH4Z
Created by admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
PRIMARY
DRUG BANK
DB12311
Created by admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID90171455
Created by admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY